Pharmaceutical Industry Turns to AI to Combat $236 Billion Patent Cliff Crisis
核心洞察
The pharmaceutical industry faces a massive patent cliff between 2025-2030, with an estimated $236 billion in US revenues at risk as major blockbuster drugs lose patent protection.
Companies like Eli Lilly, AstraZeneca, and GSK are increasingly investing in AI partnerships and acquisitions to accelerate drug development and reduce R&D costs.
AI biotech In Silico Medicine (搜索) has demonstrated the potential of AI-driven drug development, reducing candidate selection time to just 13 months compared to traditional 10-15 year timelines.
Pharmaceutical giants are racing to deploy artificial intelligence as a strategic weapon against an unprecedented wave of patent expirations threatening to strip $236 billion from US revenues alone between 2025 and 2030. This looming "patent cliff" represents one of the most significant revenue challenges the industry has faced, prompting companies to fundamentally rethink their approach to drug development and pipeline management.
According to GlobalData Strategic Intelligence, the global share of drugs protected under patents will fall from 6% to 4% during the 2024-2030 period. This dramatic shift echoes a similar trend from over a decade ago when patent-protected drugs dropped from 14% in 2007 to 10% in 2010, affecting major blockbusters like Boehringer Ingelheim's Flomax (tamsulosin), Pfizer's Lipitor (atorvastatin), and MSD's Cozaar (losartan).
AI Emerges as Strategic Solution
The transformative potential of AI has captured particular attention from big pharma as companies seek alternatives to traditional acquisition-heavy strategies. Recent high-profile deals underscore this shift: Eli Lilly announced a landmark AI supercomputer project with NVIDIA (搜索) in October 2025, while AstraZeneca acquired Modella AI (搜索) in January 2026. GSK simultaneously acquired AI capabilities from London-based Noetik (搜索) and California-based Helix (搜索).
"[AI is] increasingly seen as a way to strengthen internal R&D productivity," says George El-Helou, GlobalData Healthcare analyst, highlighting big pharma's push to move away from relying on a few blockbusters toward a steadier flow of differentiated assets.
The appeal of AI lies in its potential to drastically speed up drug development and reduce costs. AI biotech In Silico Medicine (搜索) exemplifies this transformation, reporting an average time of just 13 months from project initiation to candidate selection in a 2025 Nature Medicine paper on its AI-developed drug rentosertib (搜索). In a Phase IIa idiopathic pulmonary fibrosis (搜索) study, the drug demonstrated safety and positive signals in increasing lung function.
Industry Partnerships Signal Confidence
In Silico has secured multiple pharma partnerships, including deals with Qilu Pharmaceutical (搜索) and Servier announced this year, plus a potentially $100 million deal with Eli Lilly in November 2025. "We are condensing the risk profile. Pharma partners are looking for certainty," says Alex Zhavoronkov, CEO of In Silico. "This allows us to replenish portfolios before patent expiries begin to impact the bottom line, potentially ending the era of 'desperation M&A'."
Similarly, AI-enabled drug developer Valo Health (搜索) attracted MSD's attention with a $3 billion deal in November 2025 to find therapeutic targets for Parkinson's disease (搜索). "It's almost like we're acting as the external R&D engines to complement [pharma's] internal R&D engines," states Brian Alexander, CEO of Valo Health.
Companies Most at Risk
Bristol Myers Squibb (搜索) faces particular vulnerability, set to lose exclusivity for blockbusters Eliquis (apixaban) and Opdivo (nivolumab) during this period. Pfizer and Novartis also rank among the most exposed companies, according to El-Helou's analysis.
Meanwhile, the competitive landscape is reshuffling dramatically. Eli Lilly's GLP-1 receptor agonist tirzepatide, marketed as Mounjaro and Zepbound, is projected to replace MSD's Keytruda (pembrolizumab) as the world's top-selling drug by 2030, with Lilly's revenues expected to increase 105%.
Rising Development Costs Compound Challenges
The patent cliff crisis coincides with escalating R&D expenses driven by more specialized science, larger trial footprints, and greater operational demands. Clinical trials face increased complexity through narrow inclusion criteria, higher endpoint numbers, biomarker requirements, and more protocol adjustments. Regulatory expectations for evidence, data quality, and patient representation have also intensified.
"All of these pressures together are contributing to slowing R&D productivity. It's taking longer, costing more, and requiring significantly more data to bring a new therapy to market," El-Helou explained at the Clinical Data Management Innovation Europe 2025 conference.
Traditional Strategies Remain Relevant
Despite AI's promise, pharmaceutical companies continue employing established patent cliff mitigation strategies. Secondary patents frequently extend branded drug lifecycles, as demonstrated by Keytruda's formulation patents for subcutaneous delivery extending beyond 2040, despite its core chemical patent expiring in 2028.
This "patent thicket" approach allows branded developers to "flatten the curve" of falling revenues by enabling their formulations to compete on convenience and breadth of use rather than price alone, according to Stephan Neuhaus, partner and patent litigator at A&O Shearman.
Measured Expectations for AI Impact
While some experts like Andrée Bates, CEO of AI consultancy Eularis, suggest AI could render patent cliffs obsolete, others maintain more tempered expectations. "AI may not abolish patent cliffs for good, but it could ease falling revenues into gentler slopes," Neuhaus observes, noting that unpredictable variables can still disrupt pipeline plans despite AI management.
The industry's strategic pivot toward AI reflects a broader transformation in therapeutic focus areas, with metabolic disorders and peptide-based drugs increasingly dominating future top-sellers, while oncology, though still important, no longer holds its previous monopoly on blockbuster revenues.